Evidence check: Pharmakogenetik Medicheck in the context of fatigue

Pharmacogenetic (PGx) testing can reveal how an individual metabolizes drugs via enzymes like CYP450. In the context of fatigue, a PGx check might theoretically identify whether a medication (e.g., antidepressant, statin) is being processed too slowly or too quickly, leading to side effects or inefficacy. However, the evidence for routine PGx screening in fatigue without a specific drug regimen is weak. Most research focuses on drug response phenotypes, not fatigue as a primary endpoint. Effect sizes of common variants are moderate at best. Therefore, a PGx test may be useful only if the patient is already on medication and a pharmacogenetic issue is suspected. Without a thorough medical workup and medication history, the test lacks clinical utility. Fatigue is multifactorial (sleep, nutrition, stress, hormones, infections) and should be evaluated by a physician first. MyBody-X provides genetic data but not a diagnosis. The evidence level for this specific use case is 'unclear' because no robust studies directly link PGx testing to fatigue management.